Juvéderm
ULTRA™ XC

ALLERGAN

72352ED10B
Revision 2010-06-17

ALLERGAN

Manufacturer:
ALLERGAN
Route de Promery
Zone Artisanale de Pré-Mairy
74370 PRINGY-FRANCE

Australian Distributor:
ALLERGAN
Australia Pty Ltd
GORDON NSW 2072

New Zealand Distributor :
ALLERGAN
New Zealand limited
Cnr Manu Tapu Drive & Joseph Hammond Place
Auckland International Airport
Mangere Auckland 1
New Zealand

CE
0459
(2008)

72360ED10B

Teoxane S.A.
Exhibit 1055



COMPOSITION

Hyaluronic Acid gel	24 mg
Lidocaine hydrochloride	3 mg
Phosphate buffer pH 7.2 q.s.	1 mL

One syringe contains 0.8mL of ***Juvéderm ULTRA™ XC***.

DESCRIPTION

Juvéderm ULTRA™ XC is a sterile, pyrogen-free, physiological solution of cross-linked hyaluronic acid which is not of animal origin. The gel is presented in a graduated, pre-filled, disposable syringe.
Each box contains two 0.8mL ***Juvéderm ULTRA™ XC*** syringes, 4 single-use 30G1/2" sterile needles to be used only for injecting ***Juvéderm ULTRA™ XC***, an instruction leaflet and a set of labels in order to ensure traceability.

STERILISATION

The contents of the ***Juvéderm ULTRA™ XC*** syringes are sterilised by moist heat.
The 30G1/2" needles are sterilised by radiation.

INDICATIONS

Juvéderm ULTRA™ XC is an injectable implant used for filling any medium-sized depressions of the skin via mid-dermis injection, as well as lip definition and pouting of lips.
The presence of lidocaine is meant to reduce the patient's pain during treatment.

CONTRA-INDICATIONS

• Do not inject ***Juvéderm ULTRA™ XC*** in the eyelids.
The application of ***Juvéderm ULTRA™ XC*** in the under-eye area is to be performed only by specialists specifically trained in this technique who have a sound knowledge of the physiology of this particular area.
• Do not overcorrect.
• ***Juvéderm ULTRA™ XC*** must not be used in:
- Patients suffering from untreated epilepsy;
- Patients with known hypersensitivity to hyaluronic acid;
- Patients with known hypersensitivity to lidocaine or to amide-type local anaesthetics;
- Patients suffering from porphyria;

• ***Juvéderm ULTRA™ XC*** should not be used simultaneously with laser treatment, deep chemical peels or dermabrasion.
For surface peels, it is recommended not to inject the product if the inflammatory reaction generated is significant.

PRECAUTIONS FOR USE

• ***Juvéderm ULTRA™ XC*** must not be used in patients who tend to develop hypertrophic scarring.
• ***Juvéderm ULTRA™ XC*** must not be used in women who are pregnant or breastfeeding.
• ***Juvéderm ULTRA™ XC*** must not be used in children.
• ***Juvéderm ULTRA™ XC*** is indicated only for intra-dermal injections and injections in the mucous membrane of the lips.
• As a matter of general principle, injection of a medical device is associated with a risk of infection.
• There is no available clinical data (efficiency, tolerance) about injection of ***Juvéderm ULTRA™ XC*** into an area which has already been treated with another filling product. It is recommended not to inject it in site which has been treated with a permanent implant.
• No clinical data is available regarding the efficiency and tolerance of ***Juvéderm ULTRA™ XC*** injections in patients having a history of, or currently suffering from, autoimmune disease. The medical practitioner shall therefore decide on the indication on a case-by-case basis, according to the nature of the disease and its corresponding treatment, and shall also ensure the specific monitoring of these patients. In particular, it is recommended that these patients undergo a preliminary dual test, and to refrain from injecting the product if the disease is active.
• There is no available clinical data concerning the tolerance of the ***Juvéderm ULTRA™ XC*** injection in patients presenting a history of severe multiple allergies or anaphylactic shock. The medical practitioner shall therefore decide on the indication on a case-by-case basis, according to the nature of the allergy, and shall also ensure the specific monitoring of these at-risk patients. In particular, the decision may be taken to propose a double test or suitable preventive treatment prior to any injection.

• Patients showing a history of streptococcal disease (recurrent sore throats, acute rheumatic fever) shall be subjected to a dual test before any injection is administered. In the event of acute rheumatic fever with heart complications, it is recommended not to inject the product.
• Patients undergoing anti-coagulant treatment must be warned of the increased risk of haematomas and bleeding during the injection.
In the same way, it is recommended to avoid taking aspirin or high doses of vitamin C the week before the injection.
• The combination of ***Juvéderm ULTRA™ XC*** with certain drugs that reduce or inhibit hepatic metabolism (cimetidine, beta-blockers, etc.) is inadvisable.
• ***Juvéderm ULTRA™ XC*** should be used with caution in patients showing symptoms of cardiac conduction disorders.
• Please recommend that the patient not use any makeup during the 12 hours following the injection treatment and that any extended exposure to the sun, UV rays and temperatures below 0°C be avoided, as well as any sauna or Turkish bath sessions during the two weeks following the injection treatment.
• If the needle is blocked, do not increase the pressure on the plunger rod but stop the injection and replace the needle.
• Athletes should be made aware that this product contains an active principle that may produce a positive result in anti-doping tests.
• Medical practitioners must take into account the fact that this product contains lidocaine.
• The composition of this product is compatible with fields used for magnetic resonance imaging.

INCOMPATIBILITIES

Hyaluronic acid is known to be incompatible with quaternary ammonium salts such as benzalkonium chloride. ***Juvéderm ULTRA™ XC*** should never therefore be placed in contact with these substances or with medical-surgical instrumentation which has been treated with this type of substance.
There is no known interaction with other local anaesthetics.

UNDESIRABLE EFFECTS

The patients must be informed that they are potential side effects associated with implantation of this product, which may occur immediately or may be delayed. These include, but are not limited to:
• Inflammatory reactions (redness, oedema, erythema, etc.) which may be associated with itching or pain on pressure or both, occurring after the injection. These reactions may last for a week.
• Haematomas.
• Induration or nodules at the injection site.
• Staining or discolouration of the injection site.
• Poor effect or weak filling effect.
• Cases of necroses in the glabellar region, abscesses, granuloma and immediate or delayed hypersensitivity after hyaluronic acid and/or lidocaine injections have been reported. It is therefore advisable to take these potential risks into account.
• Patients must report inflammatory reactions which persist for more than one week or any other secondary effect which develops, to their medical practitioner as soon as possible. The medical practitioner should use an appropriate treatment.
• Any other undesirable side effects associated with injection of ***Juvéderm ULTRA™ XC*** must be reported to the distributor and/or to the manufacturer.

METHOD OF USE – POSOLOGY

• This product is designed to be injected into the dermis or the mucous membrane of the lips by an authorized medical practitioner in accordance with local applicable regulation.
As precision is essential to a successful treatment, the product must be used by medical practitioners who have undertaken specific training in injection techniques for filling.
• Before starting treatment patients should be informed of the product's indications, contra-indications, incompatibilities and potential undesirable effects.
• The area to be treated should be disinfected thoroughly prior to the injection.

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.